Navigation Links
Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
Date:10/26/2012

Researchers at Moffitt Cancer Center and the University of South Florida have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes. The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient's genetic profile.

The study appears in the October issue of Brain, Behavior, and Immunity.

"Few studies have examined the role of genes in cancer-related fatigue and none, to our knowledge, have examined genetic variation related to androgen deprivation therapy," said study co-principal investigator Heather S.L. Jim, Ph.D., assistant member of the Health Outcomes and Behavior Program. "We found that prostate cancer patients who carry the variants of the IL6 and TNFA genes and are treated with androgen deprivation therapy are susceptible to heightened fatigue."

Evidence from prostate cancer studies suggests that pro-inflammatory cytokines, which have been linked to fatigue in cancer patients, are influenced by testosterone. At the same time, testosterone inhibits IL6 gene expression. Androgen deprivation therapy restricts testosterone.

"The goal of our study was to examine whether single nucleotide polymorphisms in genes that regulate pro-inflammatory cytokines can predict changes in fatigue in men receiving androgen deprivation therapy," said co-principal investigator Paul B. Jacobsen, Ph.D., associate center director for Cancer Prevention & Control at Moffitt. "We hypothesized that patients displaying variants at these sites would display greater increases in fatigue following initiation of androgen deprivation therapy."

The researchers found that patients with a greater number of variants reported greater increases in fatigue and of longer duration.

"It is still unclear why IL6 and TNFA genotypes affected some aspects of fatigue but not others," Jim said. "While the single nucleotide polymorphisms found in our study were located in predicted transcription factor binding sites that regulate gene expression, a single gene can have many regulatory sites scattered across the genome."

The authors speculated that new single nucleotide polymorphisms may be uncovered that will help to clarify the mechanisms of inflammatory gene transcription as they relate to fatigue in cancer patients. Preliminary findings from this study "represent an important first step in identifying genetic variation as a predictor of fatigue secondary to androgen deprivation therapy," the researchers concluded.

"Early identification of patients with genetic risk factors can enable clinicians to provide timely interventions, behavioral or pharmacologic, to prevent or reduce fatigue," Jacobsen said. "This goal is consistent with personalized cancer treatment tailored to individual gene profiles to maximize benefit and minimize side effects."


'/>"/>
Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researcher investigates 2-drug synergy to treat drug-resistant chronic myeloid leukemia
2. Moffitt researchers identify unique immune gene signature across thousands of patients solid tumors
3. Moffitt Cancer Center researcher receives $2.1 million grant from NCI for answering Provocative Question
4. Moffitt cancer center researchers find novel predictor for MDS progression risk
5. Moffitt researchers say race affect likelihood of finding suitable stem cell donor
6. Moffitt Cancer Center researchers study childhood melanoma characteristics
7. Moffitt Cancer Center researchers find acidic pH microenvironments in tumors aid tumor cell survival
8. Review finds some evidence for chemo brain in breast cancer survivors, Moffitt Cancer Center says
9. Moffitt Cancer Center researchers and colleagues identify PHF20, a regulator of gene P53
10. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
11. Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata ... Spiritual Awakening, is happy to announce her “Spring Rejuvenation in Sedona” personally ... individual customized retreats offer the winter-weary soul an excellent opportunity to come out ...
(Date:2/27/2017)... Nashville, TN (PRWEB) , ... February 27, 2017 , ... ... Dot Clayton went to work for a company involved in the underground testing of ... , In “Dying for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... Periodontitis is a chronic inflammatory gum condition that occurs when the bacteria in plaque ... cleaning, also referred to as a scaling and root planing or SRP, and can ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate ... and video system brings songs, movies, TV shows and much more apps for user ... high-definition sound. An immersive view of 1280 x 720 provides crisp images with remarkable ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based ... In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... company had 800 customers and 2,250 RCEs at the time of acquisition. In ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... for RGN-137, GtreeBNT Co., Ltd., received a positive ... 3 clinical trial design for RGN-137 to treat ... healing gel that incorporates Thymosin beta 4 ("Tß4") ...
(Date:2/27/2017)... February 27, 2017 Leading Countries, Technologies and ... is expected to grow at a CAGR of 8.9% from 2016-2021 ... grow at a CAGR of 9.1% from 2016 to 2027. The ... ... will benefit you Read on to discover how you can ...
(Date:2/27/2017)... The Hague, The Netherlands , Feb 27, 2017 /PRNewswire/ ... Sectra Tiger/R is approved by NATO for use at ... requirements on security imposed within the NATO organization for the ... ... aimed at providing government authorities with an eavesdrop-secure smartphone solution. ...
Breaking Medicine Technology: